Know How Inpefa Stacks Up to Other SGLT2 Inhibitors

July 2023

New Inpefa (sotagliflozin) will try to compete with other SGLT2 inhibitors (Farxiga, Jardiance, etc).

Inpefa is NOT approved for managing type 2 diabetes yet...although A1c lowering seems similar to other SGLT2 inhibitors.

Instead, expect reps to tout Inpefa to reduce heart failure risk...especially for patients with a recent HF hospitalization.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote